{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:33:21Z","timestamp":1794893601327,"version":"4.9.1"},"reference-count":36,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Blockade of\u00a0the PD-1 axis has modest efficacy in diffuse large B-cell lymphoma (DLBCL), but data regarding LAG3 are sparse. The impact of LAG3 digital gene expression was tested in 309 patients with DLBCL treated with standard chemoimmunotherapy. Cellular distribution of LAG3 protein was determined by immunohistochemistry and flow cytometry. In tumor-infiltrating lymphocytes (TILs), LAG3 expression was highest on CD4+\u00a0regulatory T cells (Tregs) and was also highly expressed on CD8+\u00a0T cells compared with CD4+\u00a0non-Tregs (both\u00a0P\u00a0= .008). LAG3high\u00a0TILs were enriched in PD-1 and TIM-3. LAG3 was also expressed on a proportion of malignant B cells, and these patients had significantly higher LAG3 messenger RNA in their biopsies (P\u00a0= .03). LAG3high\u00a0gene expression was\u00a0associated with inferior survival in discovery\/validation cohorts, independent of cell of origin and the international prognostic index. Patients who were PD-L1high\u00a0were fivefold more likely to be LAG3high\u00a0(P\u00a0&amp;lt; .0001). Patients who were LAG3high\/PD-L1high\u00a0had an inferior progression-free survival (P\u00a0= .011) and overall survival (P\u00a0= .005) compared with patients who were LAG3low\/PD-L1high. Digital spatial protein analysis confirms LAG3 expression on T cells and, surprisingly, tumor-associated macrophages (TAMs) at higher levels than found on CD20+\u00a0B cells in the tumor microenvironment. LAG3 is frequently expressed on CD4+\u00a0Tregs and CD8+\u00a0TILs, typically with other immune checkpoints, and is also present in a proportion of malignant B cells in DLBCL and in areas enriched for TAMs. LAG3high\u00a0expression is associated with poor outcome independent of conventional prognosticators.\u00a0<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001390","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T15:58:11Z","timestamp":1586361491000},"page":"1367-1377","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":96,"title":["LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-9934","authenticated-orcid":false,"given":"Colm","family":"Keane","sequence":"first","affiliation":[{"name":"Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD, Australia;"},{"name":"Princess Alexandra Hospital, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0782-6951","authenticated-orcid":false,"given":"Soi C.","family":"Law","sequence":"first","affiliation":[{"name":"Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-9503","authenticated-orcid":false,"given":"Clare","family":"Gould","sequence":"first","affiliation":[{"name":"University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Birch","sequence":"first","affiliation":[{"name":"Pathology Queensland, Princess Alexandra Hospital, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed B.","family":"Sabdia","sequence":"first","affiliation":[{"name":"Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Merida de Long","sequence":"first","affiliation":[{"name":"Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Thillaiyampalam","sequence":"first","affiliation":[{"name":"University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Abro","sequence":"first","affiliation":[{"name":"Princess Alexandra Hospital, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua W.","family":"Tobin","sequence":"first","affiliation":[{"name":"Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Tan","sequence":"first","affiliation":[{"name":"Division of Hematopathology, Department of Pathology, Duke University School of Medicine, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7615-3949","authenticated-orcid":false,"given":"Zijun Y.","family":"Xu-Monette","sequence":"first","affiliation":[{"name":"Division of Hematopathology, Department of Pathology, Duke University School of Medicine, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"first","affiliation":[{"name":"Division of Hematopathology, Department of Pathology, Duke University School of Medicine, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Gifford","sequence":"first","affiliation":[{"name":"Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, Australia;"},{"name":"Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gabreilli","sequence":"first","affiliation":[{"name":"Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, Australia;"},{"name":"Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Stevenson","sequence":"first","affiliation":[{"name":"Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, Australia;"},{"name":"Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Gill","sequence":"first","affiliation":[{"name":"NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Talaulikar","sequence":"first","affiliation":[{"name":"Canberra Hospital, Canberra, ACT, Australia;"},{"name":"Australia National University Medical School, Canberra, ACT, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv","family":"Jain","sequence":"first","affiliation":[{"name":"Canberra Hospital, Canberra, ACT, Australia;"},{"name":"Australia National University Medical School, Canberra, ACT, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Hernandez","sequence":"first","affiliation":[{"name":"Pathology Queensland, Princess Alexandra Hospital, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Jane","family":"Halliday","sequence":"first","affiliation":[{"name":"Pathology Queensland, Princess Alexandra Hospital, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3110-1424","authenticated-orcid":false,"given":"Robert","family":"Bird","sequence":"first","affiliation":[{"name":"Princess Alexandra Hospital, Brisbane, QLD, Australia;"},{"name":"Pathology Queensland, Princess Alexandra Hospital, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Cross","sequence":"first","affiliation":[{"name":"Pathology Queensland, Princess Alexandra Hospital, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hertzberg","sequence":"first","affiliation":[{"name":"Prince of Wales Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1000-5393","authenticated-orcid":false,"given":"Maher K.","family":"Gandhi","sequence":"first","affiliation":[{"name":"Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD, Australia;"},{"name":"Princess Alexandra Hospital, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"issue":"26","key":"2020040811380888000_B1","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","article-title":"Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma","volume":"1","author":"Merryman","year":"2017","journal-title":"Blood Adv"},{"issue":"10","key":"2020040811380888000_B2","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","article-title":"Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study","volume":"2","author":"Keane","year":"2015","journal-title":"Lancet Haematol"},{"issue":"21","key":"2020040811380888000_B3","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2018-10-879015","article-title":"PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype","volume":"133","author":"Godfrey","year":"2019","journal-title":"Blood"},{"issue":"23","key":"2020040811380888000_B4","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020040811380888000_B5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020040811380888000_B6","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","article-title":"Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy","volume":"35","author":"Ascierto","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020040811380888000_B7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"2020040811380888000_B8","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","article-title":"Characterization of the major histocompatibility complex class II binding site on LAG-3 protein","volume":"94","author":"Huard","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2020040811380888000_B9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.immuni.2018.06.007","article-title":"LAG-3 inhibitory receptor expression identifies immunosuppressive natural regulatory plasma cells","volume":"49","author":"Lino","year":"2018","journal-title":"Immunity"},{"issue":"6","key":"2020040811380888000_B10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nm.3179","article-title":"Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells [published correction appears in Nat Med. 2014;20(10):1217]","volume":"19","author":"Gagliani","year":"2013","journal-title":"Nat Med"},{"issue":"8","key":"2020040811380888000_B11","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A","article-title":"Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)","volume":"32","author":"Workman","year":"2002","journal-title":"Eur J Immunol"},{"issue":"4","key":"2020040811380888000_B12","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/eji.200323382","article-title":"The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells","volume":"33","author":"Workman","year":"2003","journal-title":"Eur J Immunol"},{"issue":"7","key":"2020040811380888000_B13","doi-asserted-by":"crossref","first-page":"e1005761","DOI":"10.1371\/journal.ppat.1005761","article-title":"CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART","volume":"12","author":"Fromentin","year":"2016","journal-title":"PLoS Pathog"},{"issue":"1","key":"2020040811380888000_B14","doi-asserted-by":"crossref","first-page":"8495","DOI":"10.1038\/ncomms9495","article-title":"Immunological biomarkers predict HIV-1 viral rebound after treatment interruption","volume":"6","author":"Hurst","year":"2015","journal-title":"Nat Commun"},{"issue":"7","key":"2020040811380888000_B15","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2020040811380888000_B16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/ejh.13274","article-title":"The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma","volume":"103","author":"Keane","year":"2019","journal-title":"Eur J Haematol"},{"issue":"37","key":"2020040811380888000_B17","doi-asserted-by":"crossref","first-page":"61425","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"2020040811380888000_B18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2016.148965","article-title":"Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia","volume":"102","author":"Shapiro","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2020040811380888000_B19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"issue":"5-6","key":"2020040811380888000_B20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"issue":"2","key":"2020040811380888000_B21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/cei.12716","article-title":"The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma","volume":"183","author":"Jones","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"2020040811380888000_B22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"18","key":"2020040811380888000_B23","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1158\/1078-0432.CCR-19-0104","article-title":"High-plex predictive marker discovery for melanoma immunotherapy-treated patients using digital spatial profiling","volume":"25","author":"Toki","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2020040811380888000_B24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/978-1-61737-979-6_17","article-title":"Flow cytometric detection of human regulatory T cells","volume":"707","author":"Fazekas de St Groth","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"7","key":"2020040811380888000_B25","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","article-title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"J Exp Med"},{"issue":"2","key":"2020040811380888000_B26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","article-title":"On the exact distribution of maximally selected rank statistics","volume":"43","author":"Hothorn","year":"2003","journal-title":"Comput Stat Data Anal"},{"issue":"3","key":"2020040811380888000_B27","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single cell transcriptome analysis reveals disease-defining T cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"2020040811380888000_B28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2020040811380888000_B29","doi-asserted-by":"crossref","first-page":"e1026530","DOI":"10.1080\/2162402X.2015.1026530","article-title":"Several immune escape patterns in non-Hodgkin\u2019s lymphomas","volume":"4","author":"Laurent","year":"2015","journal-title":"OncoImmunology"},{"issue":"21","key":"2020040811380888000_B30","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.18632\/oncotarget.26771","article-title":"The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma","volume":"10","author":"Chen","year":"2019","journal-title":"Oncotarget"},{"issue":"16","key":"2020040811380888000_B31","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2020040811380888000_B32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.immuni.2018.07.007","article-title":"LAG3(+) regulatory T cells restrain interleukin-23-producing CX3CR1(+) gut-resident macrophages during group 3 innate lymphoid cell-driven colitis","volume":"49","author":"Bauche","year":"2018","journal-title":"Immunity"},{"issue":"12","key":"2020040811380888000_B33","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-018-0217-9","article-title":"LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII","volume":"19","author":"Maruhashi","year":"2018","journal-title":"Nat Immunol"},{"issue":"13","key":"2020040811380888000_B34","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1158\/1078-0432.CCR-14-2926","article-title":"Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer","volume":"21","author":"Giraldo","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2020040811380888000_B35","doi-asserted-by":"crossref","first-page":"e1239005","DOI":"10.1080\/2162402X.2016.1239005","article-title":"LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma","volume":"5","author":"Deng","year":"2016","journal-title":"OncoImmunology"},{"issue":"5","key":"2020040811380888000_B36","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jtho.2017.01.019","article-title":"LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1\/PD-L1 and tumor-infiltrating lymphocytes","volume":"12","author":"He","year":"2017","journal-title":"J Thorac Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1367\/1723421\/advancesadv2019001390.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1367\/1723421\/advancesadv2019001390.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T23:07:24Z","timestamp":1615158444000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/7\/1367\/454291\/LAG3-a-novel-immune-checkpoint-expressed-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001390","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]}}}